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Purpose: To determine the effectiveness of different interventions to slow down the progression of myopia in
children.
Methods: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, World Health
Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov from inception to August 2014.
We selected randomized controlled trials (RCTs) involving interventions for controlling the progression of myopia
in children with a treatment duration of at least 1 year for analysis.
Main OutcomeMeasures: The primary outcomes were mean annual change in refraction (diopters/year) and
mean annual change in axial length (millimeters/year).
Results: Thirty RCTs (involving 5422 eyes) were identiﬁed. Network meta-analysis showed that in compar-
ison with placebo or single vision spectacle lenses, high-dose atropine (refraction change: 0.68 [0.52e0.84]; axial
length change: 0.21 [0.28 to 0.16]), moderate-dose atropine (refraction change: 0.53 [0.28e0.77]; axial
length change: 0.21 [0.32 to 0.12]), and low-dose atropine (refraction change: 0.53 [0.21e0.85]; axial length
change: 0.15 [0.25 to 0.05]) markedly slowed myopia progression. Pirenzepine (refraction change: 0.29
[0.05e0.52]; axial length change: 0.09 [0.17 to 0.01]), orthokeratology (axial length change: 0.15 [0.22
to 0.08]), and peripheral defocus modifying contact lenses (axial length change: 0.11 [0.20 to 0.03])
showed moderate effects. Progressive addition spectacle lenses (refraction change: 0.14 [0.02e0.26]; axial length
change: 0.04 [0.09 to 0.01]) showed slight effects.
Conclusions: This network analysis indicates that a range of interventions can signiﬁcantly reduce myopia
progression when compared with single vision spectacle lenses or placebo. In terms of refraction, atropine,
pirenzepine, and progressive addition spectacle lenses were effective. In terms of axial length, atropine, ortho-
keratology, peripheral defocus modifying contact lenses, pirenzepine, and progressive addition spectacle lenses
were effective. The most effective interventions were pharmacologic, that is, muscarinic antagonists such as
atropine and pirenzepine. Certain specially designed contact lenses, including orthokeratology and peripheral
defocus modifying contact lenses, had moderate effects, whereas specially designed spectacle lenses showed
minimal effect. Ophthalmology 2016;123:697-708 ª 2016 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.Myopia has emerged as a worldwide public health issue and
is 1 of the 5 ocular conditions identiﬁed as immediate pri-
orities by the World Health Organization’s Global Initiative
for the Elimination of Avoidable Blindness.1 In developed
countries, myopia is the most common medical condition
requiring treatment, with an adult prevalence varying
from 15% to 49%.2 Although myopia is often highlighted
as an Asian problem, the UK 1958 birth cohort study3 and
Gutenberg Health Study4 showed a high prevalence of
myopia in Western countries. A study of university 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.students in the United Kingdom showed no signiﬁcant
difference in myopia prevalence between Asian (53.4%)
and white (50%) students.4 Furthermore, the prevalence of
myopia is increasing in both Asia and the West: in
Singapore doubling between 1987 and 1992 and 2009 and
20105 and in the United States increasing from 25% to
41.6% over a 30-year period.6
In addition to the optical impact of myopia on vision and
the associated costs of correction, myopia is a major risk
factor for ocular disease.7 Myopia increases the risk of eye697http://dx.doi.org/10.1016/j.ophtha.2015.11.010
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detachment.8,9 The risks associated with myopia are signiﬁ-
cant even in low myopes (<3 diopters [D]) and comparable
to the risks of smoking and hypertension to cardiovascular
health.9 There is also a clear dose-response relationship with
increased risks at higher levels of myopia. Myopia is the
primary risk factor for myopic maculopathy,10 which is now
the second most common cause of low vision in Beijing.11
Outside Asia, myopic maculopathy is 1 of the top 5 causes
of blindness among working-age people in the United
Kingdom,12 Ireland,12 and Israel.13
Standard clinical care currently treats only the optical and
medical consequences of myopia rather than limiting its
progression. Despite the lack of consensus on the causes of
myopia, a range of potential interventions to reduce its
progression have been tested. These have been based on
clinical observations, animal models of myopia develop-
ment, or both.14e20 Trials of such treatments have provided
a substantial evidence base, but most studies are of a single
intervention versus control, lacking direct head-to-head
comparison. Furthermore, there are inconsistencies among
trials examining the same intervention. Three meta-analyses
have shown the efﬁcacy of multifocal spectacle lenses,21
atropine,22 and increasing time outdoors23 on myopia
control. Another composite meta-analysis24 has assessed
the effects of several interventions, including eye drops,
spectacles, and contact lenses among children.
This article provides a network meta-analysis of in-
terventions proposed to reduce myopia progression. This
network approach is an extension of a traditional meta-
analysis that allows for both direct and indirect compari-
sons, even when 2 strategies have not been directly
compared.25 A network meta-analysis integrates relevant
data without losing the strength of randomization in indi-
vidual randomized controlled trials (RCTs).26 We conducted
this network meta-analysis with the aim of deriving
evidence-based clinical guidelines for myopia control in
children.Methods
Eligibility Criteria
Trials were eligible for our network meta-analysis if they (1)
compared interventions for slowing the progression of myopia to
control patients or other therapeutic interventions in children and (2)
had a treatment duration of at least 1 year. We excluded trials if they
(1) included patients agedmore than 18 years when enrolled in trials,
(2) included patients with less than 0.25 D of spherical equivalent
myopia at baseline, (3) were a nonrandomized or noncomparative
study, (4) did not have the required outcomemeasures, or (5) failed to
provide data suitable for meta-analysis. We used mean annual
change in refraction (diopters/year) and mean annual change in axial
length (millimeters/year) as our primary outcomes. We speciﬁed
tropicamide as a placebo at the outset, because a previous study
by Shih et al27 found that 0.5% tropicamide had a similar effect
to placebo on myopia progression. Likewise, single vision
spectacle lenses were prespeciﬁed as a control along with placebo.
Furthermore, the concentration of atropine was classed into 3
groups: high-dose atropine (1% and 0.5%), moderate-dose atro-
pine (0.1%), and low-dose atropine (0.01%).698Search Methods
We searched MEDLINE, EMBASE, Cochrane Central Register of
Controlled Trials, World Health Organization International Clinical
Trials Registry Platform, and ClinicalTrials.gov databases (from
inception to August 2014) for RCTs in any language. The search
strategy is shown in the Appendix (available at www.aaojournal.org).
We also examined reference lists from reports on clinical trials, meta-
analyses, and systematic reviews to identify relevant studies.
Study Selection and Data Collection
Two investigators (D.Z.W., J.H.H.) independently reviewed the
titles, abstracts, and full text articles for inclusion using standard-
ized data extraction forms. They conducted a focused discussion to
resolve any disagreements. When the same population was
involved in multiple articles, we included only the primary report
in the meta-analysis. We extracted the following information from
each trial: (1) ﬁrst author, (2) year of publication, (3) follow-up
duration, (4) type of intervention, (5) sample size, (6) baseline
characteristics (age, refraction, axial length, dropouts from total
number), and (7) end points (mean change in refraction and axial
length). For any missing data, we contacted the authors of trial
reports or used GetData GraphDigitizer 2.24 (http://getdata-graph-
digitizer.com) to read data from ﬁgures.
Risk of Bias Assessment
Study quality was assessed by Cochrane Collaboration’s risk-of-
bias method.28 The methodology examined the following aspects
of each trial: random sequence generation and allocation
concealment (both items related to selection bias), blinding of
participants and personnel (detection bias), incomplete outcome
data (attrition bias), selective reporting (reporting bias), and other
bias. We graded each of the item domains at “low,” “high,” or
“unclear” risk of bias.
Statistical Analysis
We conducted direct head-to-head comparisons using a random-
effects model to estimate weighted mean differences and 95%
conﬁdence intervals (CIs),29 and assessed heterogeneity with the I2
statistic,30 with I2 values greater than 50% indicating substantial
heterogeneity. We performed direct comparisons using STATA
version 10.0 (StataCorp LP, College Station, TX). For all
comparisons, the stated values represent the differences in ﬁnal
refraction or axial elongation between the ﬁrst intervention and
the second intervention. In terms of refractive error, a positive
mean difference therefore indicates that the ﬁrst intervention is
better (less myopia progression). In terms of axial length, a
negative mean difference indicates the ﬁrst intervention is better
(less axial elongation).
We performed aBayesian random-effects networkmeta-analyses
using WinBUGS version 1.4 (MRC Biostatistics Unit, Cambridge,
UK) to estimate pooledweightedmean differences and 95% credible
intervals (CrIs).We estimated the posterior densities for all unknown
parameters using the Markov chain Monte Carlo method for each
model. Each chain used 50 000 iterations with a burn-in number of
20 000, thin interval of 1, and updates varying between 80 and 110.
The choice of burn-in was made according to the GelmaneRubin
approach.31 The code is available from the authors on request. We
ranked treatments on the basis of the relative treatment effects
compared with placebo or single vision spectacle lenses and the
analysis of ranking probabilities. We deﬁned refraction change
0.50 D/year or axial length change 0.18 mm/year as a “strong”
effect, refraction change from 0.25 D/year to 0.50 D/year or
axial length change from 0.09 mm/year to 0.18 mm/year as a
Huang et al  Network Meta-analysis: Interventions for Myopia“moderate” effect, and refraction change from 0 to 0.25 D/year
or axial length change range from 0 to 0.09 mm/year as a “weak”
effect. Inconsistency between direct and indirect evidence was
assessed by “node-splitting.”32 Further sensitivity analyses were
undertaken by removal of trials that caused high heterogeneity in
direct comparisons. We also performed an additional network
meta-analyses in 4 subgroups of studies: subgroups 1 (16 studies)
and 2 (11 studies) examining trialswith different ethnicity (Asian and
white subjects), and subgroups 3 (20 studies) and 4 (17 studies)
examining trials with different treatment durations (1 year from
baseline and 2 years from baseline).
Results
Figure 1 shows the ﬂowchart for the study analysis. We identiﬁed
2435 articles through the electronic literature searches, and 1727
remained after removal of duplicates. After review of the titles
and abstracts of these articles, a further 1584 were excluded. On
fully evaluating the remaining 143 citations, we found 30
primary articles (4 articles with a multi-arm design) that met the
inclusion criteria in the network meta-analysis, comprising a total
of 5387 people (5422 eyes) (the Appendix shows the full details of
these 30 studies, available at www.aaojournal.org). Among the 30Figure 1. Flowchart for the study analysis. ICTRP¼ International Clinical
Trials Registry Platform.trials contributing to the analysis, 4 main types of interventions
were involved: 13 spectacle lens studies, 9 contact lenses studies,
1 outdoor activity study, and 7 pharmacologic studies. Nineteen
studies reported both refraction and axial length outcomes, 9
studies only reported refraction, and 2 studies reported only axial
length.
The quality of the included trials is shown in the Appendix
(available at www.aaojournal.org). Overall, the trials that we
included in this analysis seem to have a low to moderate risk of
bias, with most of the trials reporting adequate random sequence
generation, allocation concealment, and blinding of outcome
assessment. However, participants in most studies could not be
masked because of the physical nature of a treatment (e.g., contact
lenses versus spectacles) or its effects (e.g., pupil dilatation with
higher doses of atropine). Having unmasked participants could
increase the risk of bias. For example, if participants receive a
treatment perceived as useful, this may enhance their compliance
and vice versa.
There are some issues that should be noted: Sankaridurg et al33
reported the results of 3 designs of peripheral defocus modifying
spectacle lenses, and only the most effective design (type III, an
asymmetric design) was selected in our analyses. The study by
Anstice and Phillips34 was a cross-over trial with 2 periods, and
we used only data from the ﬁrst period (10 months) with 1-year
treatment effects.
Figure 2 shows the network of direct comparisons for the
interventions of myopia. Table 1 shows the results (refraction or
axial length change per year) of conventional meta-analyses. InFigure 2. Network of direct comparison for the interventions of myopia.
Each node represents 1 treatment. The size of the node is proportional to
the number of participants randomized to that treatment. The edges
represent direct comparisons, and the width of the edge is proportional to
the number of trials. Atr ¼ atropine; Atr H ¼ high-dose atropine (1% or
0.5%); Atr L ¼ low-dose atropine (0.01%); Atr M ¼ moderate-dose
atropine (0.1%); BSLs ¼ bifocal spectacle lenses; Cyc ¼ cyclopentolate;
MOA ¼ more outdoor activities (14e15 hrs/wk); OK ¼ orthokeratology;
PASLs ¼ progressive addition spectacle lenses; PBO ¼ placebo; PBSLs ¼
prismatic bifocal spectacle lenses; PDMCLs ¼ peripheral defocus modifying
contact lenses; PDMSLs ¼ peripheral defocus modifying spectacle lenses;
Pir ¼ pirenzepine; RGPCLs ¼ rigid gas-permeable contact lenses; SCLs ¼
soft contact lenses; SVSLs ¼ single vision spectacle lenses; Tim ¼ timolol;
USVSLs ¼ undercorrected single vision spectacle lenses.
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Table 1. Changes in Refraction and Axial Length per Year from Direct Comparisons between Each Pair of Interventions
Refraction Change, D/yr Axial Length Change, mm/yr
No. of Studies Mean Difference (95% CI) I2 No. of Studies Mean Difference (95% CI) I2
Atr H 4 0.70 (0.42e0.99) 93.9% 2 0.21 (0.25 to 0.18) 5.8%
Atr M 1 0.59 (0.43e0.75)
BSLs 4 0.09 (0.05 to 0.24) 85.6% 2 0.06 (0.10 to 0.02) 0%
Cyc 1 0.33 (0.07e0.59)
MOA 1 0.14 (0.06e0.22)
OK 2 0.14 (0.19 to 0.10) 0%
PASLs 7 0.12 (0.07e0.18) 51.1% 5 0.04 (0.07 to 0.01) 51.5%
PBSLs 1 0.34 (0.22e0.46) 1 0.09 (0.14 to 0.04)
PDMSLs 1 0.12 (0.06 to 0.30) 1 0.05 (0.12 to 0.02)
Pir 2 0.29 (0.13e0.44) 47.6% 2 0.09 (0.15 to 0.02) 0.0%
RGPCLs 1 0.03 (0.13 to 0.07) 1 0.02 (0.04 to 0.08)
SCLs 2 0.06 (0.10 to 0.02) 0.0% 1 0.01 (0.01 to 0.03)
Tim 1 0.02 (0.15 to 0.11)
USVSLs 2 0.11 (0.22 to 0.00) 0.0% 1 0.03 (0.02 to 0.08)
vs. SVSLs/PBO
Atr M 2 0.23 (0.61 to 0.15) 94.7% 1 0.00 (0.03 to 0.03)
Atr L 1 0.10 (0.19 to 0.01) 1 0.07 (0.03e0.11)
Cyc 1 0.36 (0.61 to 0.11)
PASLs 1 0.51 (0.64 to 0.38) 1 0.18 (0.13e0.23)
vs. Atr H
Atr M 1 0.06 (0.03 to 0.15) 1 0.07 (0.11 to 0.03)
vs. Atr L
PBSLs 1 0.08 (0.03 to 0.19) 1 0.01 (0.07 to 0.05)
Tim 1 0.11 (0.23 to 0.01)
vs. BSLs
SCLs 3 0.31 (0.60 to 0.02) 90.6% 3 0.12 (0.05e0.19) 82.3%
vs. PDMCLs
SCLs 1 0.21 (0.34 to 0.08) 1 0.02 (0.09 to 0.05)
vs. RGPCLs
Atr ¼ atropine; Atr H ¼ high-dose atropine (1% or 0.5%); Atr L ¼ low-dose atropine (0.01%); Atr M ¼ moderate-dose atropine (0.1%); BSLs ¼ bifocal
spectacle lenses; CI ¼ conﬁdence interval; Cyc ¼ cyclopentolate; D ¼ diopter; MOA ¼ more outdoor activities (14e15 hrs/wk); OK ¼ orthokeratology;
PASLs ¼ progressive addition spectacle lenses; PBO ¼ placebo; PBSLs ¼ prismatic bifocal spectacle lenses; PDMCLs ¼ peripheral defocus modifying
contact lenses; PDMSLs ¼ peripheral defocus modifying spectacle lenses; Pir ¼ pirenzepine; RGPCLs ¼ rigid gas-permeable contact lenses; SCLs ¼ soft
contact lenses; SVSLs ¼ single vision spectacle lenses; Tim ¼ timolol; USVSLs ¼ undercorrected single vision spectacle lenses.
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following interventions were all found to be effective with statis-
tically signiﬁcant effect (P < 0.05): high-dose atropine (refraction
change: 0.70 D, 95% CI, 0.42e0.99; axial length change: 0.21
mm, 95% CI, 0.25 to 0.18), moderate-dose atropine (refraction
change: 0.59 D, 95% CI, 0.43e0.75), cyclopentolate (refraction
change: 0.33 D, 95% CI, 0.07e0.59), more outdoor activities
(refraction change: 0.14 D, 95% CI, 0.06e0.22), orthokeratology
(axial length change: 0.14 mm, 95% CI, 0.19 to 0.10), pro-
gressive addition spectacle lenses (refraction change: 0.12 D, 95%
CI, 0.07e0.18; axial length change: 0.04 mm, 95% CI, 0.07
to 0.01), prismatic bifocal spectacle lenses (refraction change:
0.34 D, 95% CI, 0.22e0.46; axial length change: 0.09 mm, 95%
CI, 0.14 to 0.04), and pirenzepine (refraction change: 0.29 D,
95% CI, 0.13e0.44; axial length change: 0.09 mm, 95%
CI, 0.15 to 0.02). On direct comparison, high-dose atropine
was superior (P < 0.05) to low-dose atropine (refraction change:
0.10 D, 95% CI, 0.01e0.19; axial length change: 0.07 mm, 95%
CI, 0.11 to 0.03), cyclopentolate (refraction change: 0.36 D,
95% CI, 0.11e0.61), and progressive addition spectacle lenses
(refraction change: 0.51 D, 95% CI, 0.38e0.64; axial length
change: 0.18 mm, 95% CI, 0.23 to 0.13). Direct comparison
of peripheral defocus modifying contact lenses (refraction change:
0.31 D, 95% CI, 0.02e0.60; axial length change: 0.12 mm, 95%
CI, 0.19 to 0.05) and rigid gas-permeable contact lenses700(refraction change: 0.21 D, 95% CI, 0.08 to 0.34) showed
superiority (P < 0.05) to soft contact lenses.
There was heterogeneity among some within-trial comparisons
(I2 > 50%), for example, high-dose atropine (1% and 0.5%)
versus placebo (refraction change: 0.70 D, 95% CI, 0.42e0.99,
I2 ¼ 93.9%), bifocal spectacle lenses versus single vision
spectacle lenses (refraction change: 0.09 D, 95% CI, 0.05 to 0.24,
I2 ¼ 85.6%), progressive addition spectacle lenses versus single
vision spectacle lenses (refraction change: 0.12 D, 95% CI, 0.07
to 0.18, I2 ¼ 51.1%; axial length change: 0.04 mm, 95%
CI, 0.07 to 0.01, I2 ¼ 51.5%), high-dose atropine (1% and
0.5%) versus moderate-dose atropine (0.1%) (refraction change:
0.23 D, 95% CI, 0.15 to 0.61, I2 ¼ 94.7%), and peripheral
defocus modifying contact lenses versus soft contact lenses
(refraction change: 0.31 D, 95% CI, 0.02e0.6, I2 ¼ 90.6%; axial
length change: 0.12 mm, 95% CI, 0.019 to 0.05, I2 ¼ 82.3%).
The forest plots demonstrating this heterogeneity are shown in the
Appendix (available at www.aaojournal.org).
We also performed a random effects network meta-analysis
combining the direct and indirect evidence to compare different
interventions with single vision spectacle lenses/placebo (Fig 3)
and with each other (Fig 4). As shown in Figure 3 and Table 2,
in comparison with placebo or single vision spectacle lenses,
high-dose atropine (refraction change: 0.68 D, 95% CrI,
0.52e0.84; axial length change: 0.21 mm, 95% CrI, 0.28
Figure 3. Results of network meta-analysis using single vision spectacle lenses/placebo as referent intervention. Atr ¼ atropine; Atr H ¼ high-dose atropine
(1% or 0.5%); Atr L ¼ low-dose atropine (0.01%); Atr M ¼ moderate-dose atropine (0.1%); BSLs ¼ bifocal spectacle lenses; CrI ¼ credible interval; Cyc ¼
cyclopentolate; MOA ¼ more outdoor activities (14e15 hrs/wk); OK ¼ orthokeratology; PASLs ¼ progressive addition spectacle lenses; PBO ¼ placebo;
PBSLs ¼ prismatic bifocal spectacle lenses; PDMCLs ¼ peripheral defocus modifying contact lenses; PDMSLs ¼ peripheral defocus modifying spectacle
lenses; Pir ¼ pirenzepine; RGPCLs ¼ rigid gas-permeable contact lenses; SCLs ¼ soft contact lenses; SVSLs ¼ single vision spectacle lenses; Tim ¼ timolol;
USVSLs ¼ undercorrected single vision spectacle lenses.
Figure 4. Network meta-analysis comparing all interventions of myopia. Atr ¼ atropine; Atr H ¼ high-dose atropine (1% or 0.5%); Atr L ¼ low-dose
atropine (0.01%); Atr M ¼ moderate-dose atropine (0.1%); BSLs ¼ bifocal spectacle lenses; CrI ¼ credible interval; Cyc ¼ cyclopentolate;
MOA ¼ more outdoor activities (14e15 hrs/wk); OK ¼ orthokeratology; PASLs ¼ progressive addition spectacle lenses; PBO ¼ placebo;
PBSLs ¼ prismatic bifocal spectacle lenses; PDMCLs ¼ peripheral defocus modifying contact lenses; PDMSLs ¼ peripheral defocus modifying spectacle
lenses; Pir ¼ pirenzepine; RGPCLs ¼ rigid gas-permeable contact lenses; SCLs ¼ soft contact lenses; SVSLs ¼ single vision spectacle lenses; Tim ¼ timolol;
USVSLs ¼ undercorrected single vision spectacle lenses.
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Table 2. Treatment Effect Relative to Single Vision Spectacle Lenses/Placebo Based on the Network Meta-analysis
Ineffective
R: £0 D/yr
AL: ‡0 mm/yr
Weak
R: 0 to 0.25 D/yr
AL: 0 to L0.09 mm/yr
Moderate
R: 0.25 to 0.50 D/yr
AL: L0.09 to L0.18 mm/yr
Strong
R: ‡0.50 D/yr
AL: £ L0.18 mm/yr
Atr H R: 0.68 (0.52e0.84)
AL: 0.21 (0.28 to 0.16)
Atr M R: 0.53 (0.28e0.77)
AL: 0.21 (0.32 to 0.12)
Atr L AL: 0.15 (0.25 to 0.05) R: 0.53 (0.21e0.85)
Pir AL: 0.09 (0.17 to 0.01) R: 0.29 (0.05e0.52)
PDMCLs R: 0.21 (0.07 to 0.48) AL: 0.11 (0.20 to 0.03)
OK AL: 0.15 (0.22 to 0.08)
PBSLs AL: 0.08 (0.16 to 0.00) R: 0.25 (0.03 to 0.54)
Cyc R: 0.33 (0.02 to 0.67)
PASLs R: 0.14 (0.02e0.26)
AL: 0.04 (0.09 to 0.01)
BSLs R: 0.09 (0.07 to 0.25)
AL: 0.06 (0.12 to 0.00)
PDMSLs R: 0.12 (0.24 to 0.47)
AL: 0.05 (0.15 to 0.05)
MOA R: 0.14 (0.17 to 0.46)
RGPCLs AL: 0.02 (0.05 to 0.10) R: 0.04 (0.21 to 0.29)
Tim R: 0.02 (0.31 to 0.27)
SCLs R: 0.09 (0.29 to 0.10)
AL: 0.01 (0.06 to 0.07)
USVSLs R: 0.11 (0.35 to 0.13)
AL: 0.03 (0.06 to 0.11)
AL¼ axial length change; Atr ¼ atropine; Atr H¼ high-dose atropine (1% or 0.5%); Atr L ¼ low-dose atropine (0.01%); Atr M ¼ moderate-dose atropine
(0.1%); BSLs ¼ bifocal spectacle lenses; Cyc ¼ cyclopentolate; D ¼ diopter; MOA ¼ more outdoor activities (14e15 hrs/wk); OK ¼ orthokeratology;
PASLs ¼ progressive addition spectacle lenses; PBO ¼ placebo; PBSLs ¼ prismatic bifocal spectacle lenses; PDMCLs ¼ peripheral defocus modifying
contact lenses; PDMSLs ¼ peripheral defocus modifying spectacle lenses; Pir ¼ pirenzepine; R ¼ refraction change; RGPCLs ¼ rigid gas-permeable contact
lenses; SCLs ¼ soft contact lenses; SVSLs ¼ single vision spectacle lenses; Tim ¼ timolol; USVSLs ¼ undercorrected single vision spectacle lenses.
The underlined data indicate that there are statistically signiﬁcant effects (P < 0.05). A 0.18-mm axial length change is estimated to produce a 0.50 D
change in refraction.
Ophthalmology Volume 123, Number 4, April 2016to 0.16), moderate-dose atropine (refraction change: 0.53 D, 95%
CrI, 0.28e0.77; axial length change: 0.21 mm, 95% CrI, 0.32
to 0.12), and low-dose atropine (refraction change: 0.53 D, 95%
CrI, 0.21e0.85; axial length change: 0.15 mm, 95% CrI, 0.25
to 0.05) markedly slowed myopia progression. Pirenzepine
(refraction change: 0.29 D, 95% CrI, 0.05e0.52; axial length
change: 0.09 mm, 95% CrI, 0.17 to 0.01), orthokeratology
(axial length change: 0.15 mm, 95% CrI, 0.22 to 0.08), and
peripheral defocus modifying contact lenses (axial length
change: 0.11 mm, 95% CrI, 0.20 to 0.03) showed moderate
effects. Progressive addition spectacle lenses (refraction change:
0.14 D, 95% CrI, 0.02e0.26; axial length change: 0.04 mm, 95%
CrI, 0.09 to 0.01) showed weak effects, and rigid gas-
permeable contact lenses, soft contact lenses, undercorrected sin-
gle vision spectacle lenses, and timolol were ineffective in slowing
myopia progression. The pairwise comparisons of all interventions
(Fig 4) shows that high-dose atropine (1% and 0.5%) was signif-
icantly superior (P < 0.05) to other interventions in refraction
change or axial length change, with the exception of moderate-dose
atropine (0.1%) (refraction change: 0.15 D, 95% CrI, 0.07 to
0.37; axial length change: 0.00 mm, 95% CrI, 0.08 to 0.08),
low-dose atropine (0.01%) (refraction change: 0.15 D, 95%
CrI, 0.14 to 0.45; axial length change: 0.07 mm, 95%
CrI, 0.15 to 0.01), and orthokeratology (axial length
change: 0.07, 95% CrI 0.16 to 0.02). There were no signiﬁcant
differences (P > 0.05) among bifocal spectacle lenses, cyclo-
pentolate, more outdoor activities, orthokeratology, progressive
addition spectacle lenses, prismatic bifocal spectacle lenses,702peripheral defocus modifying contact lenses, peripheral defocus
modifying spectacle lenses, and pirenzepine in pairwise compari-
sons, with the exception of orthokeratology versus progressive
addition spectacle lenses (axial length change: 0.11 mm, 95%
CrI, 0.18 to 0.02). Rigid gas-permeable contact lenses,
soft contact lenses, timolol, and undercorrected single vision
spectacle lenses were inferior to most other interventions, with no
signiﬁcant differences in these pairwise comparisons. The resulting
ranking probabilities are shown in the Appendix (available at
www.aaojournal.org). Node-splitting analysis of inconsistency in-
dicates no signiﬁcant discrepancies between direct and indirect
estimates (range of P values: 0.18e0.97; the Appendix shows more
details, available at www.aaojournal.org).
In sensitivity analyses (Table 3) using control as the reference
intervention, 4 trials (Shih et al,32 Parssinen et al,35 Leung and
Brown,36 and Aller and Wildsoet37) contributed high levels of
heterogeneity in the analysis and were subsequently removed. As
expected, the effects of most interventions compared with control
became a little less pronounced, but the ranking of interventions of
the network meta-analysis did not signiﬁcantly change. Subgroup
analyses (Table 4) using single vision spectacle lenses/placebo as the
reference intervention showed that in some interventions (bifocal
spectacle lenses, progressive addition spectacle lenses, and
pirenzepine) Asian children appeared to beneﬁt more from treatment
than white children, especially in the treatment with bifocal
spectacle lenses versus single vision spectacle lenses. In that
comparison, Asian children (refraction change: 0.26 D, 95%
CrI, 0.13 to 0.65; axial length change: 0.08 mm, 95%
Table 3. Results of Sensitivity Analyses Performed by Removal of Trials That Caused High Heterogeneity Across Studies Based on the
Network Meta-analysis
Original Data Sensitivity Analyses
Mean Difference (95% CrI)
in Refraction, D/yr
Mean Difference (95% CrI)
in Axial Length, mm/yr
Mean Difference (95% CrI)
in Refraction, D/yr
Mean Difference (95% CrI)
in Axial Length, mm/yr
Atr H 0.68 (0.52e0.84) 0.21 (0.28 to 0.16) 0.55 (0.45e0.68) 0.21 (0.26 to 0.17)
Atr M 0.53 (0.28e0.77) 0.21 (0.32 to 0.12) 0.51 (0.33e0.71) 0.21 (0.28 to 0.14)
Atr L 0.53 (0.21e0.85) 0.15 (0.25 to 0.05) 0.45 (0.27e0.66) 0.14 (0.22 to 0.07)
BSLs 0.09 (0.07 to 0.25) 0.06 (0.12 to 0.00) 0.16 (0.05e0.26) 0.06 (0.11 to 0.01)
Cyc 0.33 (0.02 to 0.67) NA 0.26 (0.00e0.52) NA
MOA 0.14 (0.17 to 0.46) NA 0.14 (0.02 to 0.30) NA
OK NA 0.15 (0.22 to 0.08) NA 0.14 (0.20 to 0.08)
PASLs 0.14 (0.02e0.26) 0.04 (0.09 to 0.01) 0.10 (0.03e0.17) 0.03 (0.06 to 0.00)
PBSLs 0.25 (0.03 to 0.54) 0.08 (0.16 to 0.00) 0.28 (0.12e0.45) 0.08 (0.14 to 0.02)
PDMCLs 0.21 (0.07 to 0.48) 0.11 (0.20 to 0.03) 0.07 (0.10 to 0.25) 0.08 (0.15 to 0.02)
PDMSLs 0.12 (0.24 to 0.47) 0.05 (0.15 to 0.05) 0.12 (0.11 to 0.35) 0.05 (0.13 to 0.03)
Pir 0.29 (0.05e0.52) 0.09 (0.17 to 0.01) 0.28 (0.13e0.43) 0.09 (0.16 to 0.01)
RGPCLs 0.04 (0.21 to 0.29) 0.02 (0.05 to 0.10) 0.04 (0.10 to 0.17) 0.02 (0.03 to 0.08)
SCLs 0.09 (0.29 to 0.10) 0.01 (0.06 to 0.07) 0.08 (0.19 to 0.01) 0.01 (0.04 to 0.05)
Tim 0.02 (0.31 to 0.27) NA 0.02 (0.15 to 0.19) NA
USVSLs 0.11 (0.35 to 0.13) 0.03 (0.06 to 0.11) 0.11 (0.26 to 0.04) 0.03 (0.04 to 0.10)
Atr ¼ atropine; Atr H ¼ high-dose atropine (1% or 0.5%); Atr L ¼ low-dose atropine (0.01%); Atr M ¼ moderate-dose atropine (0.1%); BSLs ¼ bifocal
spectacle lenses; CrI ¼ credible interval; Cyc ¼ cyclopentolate; D ¼ diopter; MOA ¼ more outdoor activities (14e15 hrs/wk); NA ¼ not available; OK ¼
orthokeratology; PASLs ¼ progressive addition spectacle lenses; PBO ¼ placebo; PBSLs ¼ prismatic bifocal spectacle lenses; PDMCLs ¼ peripheral defocus
modifying contact lenses; PDMSLs ¼ peripheral defocus modifying spectacle lenses; Pir ¼ pirenzepine; RGPCLs ¼ rigid gas-permeable contact lenses;
SCLs ¼ soft contact lenses; SVSLs ¼ single vision spectacle lenses; Tim ¼ timolol; USVSLs ¼ undercorrected single vision spectacle lenses.
All mean difference use SVSLs/PBO as the referent intervention.
Huang et al  Network Meta-analysis: Interventions for MyopiaCrI,0.23 to0.07) andwhite children (refraction change: 0.03D,95%
CrI,0.09 to 0.17; axial length change:0.04mm,95%CrI,0.22 to
0.13) differed by 0.23 D in refraction change and 0.05 mm in axial
length change. These differences did not reach statistical
signiﬁcance, and additional trial data are required to adequately
address the question of whether race has an impact on the efﬁcacy
of myopia control treatments. Further subgroup analyses stratiﬁed
by different treatment durations showed that most interventions lose
their early effect in the second year, especially in the protection of
axial length change.Discussion
Our study is a network meta-analysis aimed speciﬁcally at
investigating the efﬁcacy or comparative effectiveness of
different interventions to slowmyopia progression. In addition,
the present study updates previous evidence-based re-
views.24,38,39 A previous review by Saw et al39 and a more
recent Cochrane review29 both concluded that the evidence
from randomized clinical trials of that time does not provide
sufﬁcient information to support interventions to slow down
the progression of myopia. The increased availability of
high-quality clinical trials combined with the network meta-
analysis techniques used in this article can now provide some
guidance regarding the management of myopic progression.
The main ﬁndings of our analysis are as follows:1. High-dose atropine (1% and 0.5%), moderate-dose
atropine (0.1%), and low-dose atropine (0.01%)
showed clear effects in myopia control (all withstatistically signiﬁcant effect); pirenzepine, ortho-
keratology, peripheral defocus modifying contact
lenses, cyclopentolate, and prismatic bifocal spec-
tacle lenses showed moderate effects (all with sta-
tistically signiﬁcant effect except for cyclopentolate
and prismatic bifocal spectacle lenses); progressive
addition spectacle lenses, bifocal spectacle lenses,
peripheral defocus modifying spectacle lenses, and
more outdoor activities showed weak effects (only
progressive addition spectacle lenses with statisti-
cally signiﬁcant effect); rigid gas-permeable contact
lenses, soft contact lenses, undercorrected single
vision spectacle lenses, and timolol were ineffective
(all with no statistically signiﬁcant effect).
2. High-dose atropine (1% and 0.5%) was signiﬁcantly
superior to other interventions except moderate-dose
atropine (0.1%) and low-dose atropine (0.01%).
Among bifocal spectacle lenses, cyclopentolate,
more outdoor activities, orthokeratology, progres-
sive addition spectacle lenses, prismatic bifocal
spectacle lenses, peripheral defocus modifying
contact lenses, peripheral defocus modifying spec-
tacle lenses, and pirenzepine, pairwise comparisons
showed no signiﬁcant differences apart from a
beneﬁt of orthokeratology over progressive addition
spectacle lenses. Rigid gas-permeable contact len-
ses, soft contact lenses, timolol, and undercorrected
single vision spectacle lenses were inferior to most
other interventions, with no signiﬁcant differences
within this group.703
Table 4. Results of Subanalyses Using Single Vision Spectacle Lenses/Placebo as Referent Intervention Based on the Network Metaanalysis
Different Ethnicity Different Treatment Duration
Asian Children White Children 1 Yr from Baseline 2 Yrs from Baseline
Mean Difference (95%
CrI) in Refraction
Change, D/yr
Mean Difference (95% CrI)
in Axial Length Change,
mm/yr
Mean Difference (95%
CrI) in Refraction
Change, D/yr
Mean Difference (95% CrI)
in Axial Length Change,
mm/yr
Mean Difference (95%
CrI) in Refraction
Change, D
Mean Difference (95%
CrI) in Axial Length
Change, mm
Mean Difference (95%
CrI) in Refraction
Change, D
Mean Difference (95%
CrI) in Axial Length
Change, mm
Atr H 0.68 (0.49e0.88) 0.22 (0.33 to 0.12) NA NA 0.76 (0.47e1.03) 0.34 (0.49 to 0.19) 1.40 (0.76e2.05) 0.40 (0.77 to 0.04)
Atr M 0.53 (0.23e0.82) 0.22 (0.40 to 0.04) NA NA 0.61 (0.15e1.07) 0.32 (0.53 to 0.10) 1.07 (0.30e1.84) 0.39 (0.92 to 0.12)
Atr L 0.53 (0.13e0.91) 0.15 (0.33 to 0.03) NA NA 0.49 (0.03e0.96) 0.21 (0.43 to 0.00) 1.09 (0.08e2.11) 0.26 (0.78 to 0.27)
BSLs 0.26 (0.13 to 0.65) 0.08 (0.23 to 0.07) 0.03 (0.09 to 0.17) 0.04 (0.22 to 0.13) 0.16 (0.03 to 0.35) 0.12 (0.29 to 0.05) 0.21 (0.26 to 0.68) 0.21 (0.58 to 0.16)
Cyc 0.33 (0.07 to 0.73) NA NA 0.36 (0.03 to 0.75) NA NA NA
MOA 0.14 (0.25 to 0.52) NA NA NA NA 0.28 (0.66 to 1.22) NA
OK NA 0.14 (0.26 to 0.04) NA NA 0.19 (0.32 to 0.08) NA 0.29 (0.55 to 0.03)
PASLs 0.17 (0.00 to 0.34) 0.05 (0.15 to 0.03) 0.06 (0.09 to 0.22) 0.04 (0.17 to 0.08) 0.19 (0.02 to 0.40) 0.08 (0.19 to 0.00) 0.28 (0.18 to 0.75) 0.10 (0.35 to 0.09)
PBSLs 0.34 (0.06 to 0.73) 0.09 (0.24 to 0.06) NA 0.40 (0.05 to 0.76) 0.18 (0.35 to 0.01) 0.65 (0.19 to 1.52) 0.21 (0.58 to 0.17)
PDMCLs NA NA 0.50 (0.21e0.80) 0.18 (0.44 to 0.06) 0.10 (0.68 to 0.50) 0.15 (0.40 to 0.12) 0.40 (2.05 to 1.22) 0.09 (0.73 to 0.56)
PDMSLs 0.12 (0.29 to 0.54) 0.05 (0.21 to 0.11) NA 0.12 (0.26 to 0.51) 0.05 (0.20 to 0.11) NA NA
Pir 0.37 (0.04 to 0.77) 0.13 (0.31 to 0.05) 0.21 (0.03 to 0.45) 0.06 (0.24 to 0.13) 0.32 (0.06 to 0.58) 0.08 (0.21 to 0.04) 0.41 (0.57 to 1.36) 0.12 (0.51 to 0.27)
RGPCLs 0.03 (0.42 to 0.35) 0.02 (0.13 to 0.17) 0.15 (0.13 to 0.42) 0.03 (0.22 to 0.27) 0.02 (0.39 to 0.34) 0.02 (0.15 to 0.19) 0.05 (1.01 to 0.88) 0.05 (0.32 to 0.42)
SCLs NA NA 0.06 (0.21 to 0.09) 0.01 (0.16 to 0.18) 0.42 (0.96 to 0.13) 0.01 (0.25 to 0.23) 0.59 (1.94 to 0.74) 0.04 (0.48 to 0.57)
Tim NA NA 0.06 (0.26 to 0.16) NA 0.04 (0.38 to 0.30) 0.04 (0.89 to 0.82) NA
USVSLs 0.11 (0.40 to 0.18) 0.03 (0.12 to 0.18) 0.11 (0.38 to 0.16) NA 0.01 (0.29 to 0.28) 0.05 (0.10 to 0.20) 0.23 (1.19 to 0.71) 0.06 (0.31 to 0.43)
Atr ¼ atropine; Atr H ¼ high-dose atropine (1% or 0.5%); Atr L ¼ low-dose atropine (0.01%); Atr M ¼ moderate-dose atropine (0.1%); BSLs ¼ bifocal spectacle lenses; CrI ¼ credible interval; Cyc ¼
cyclopentolate; D ¼ diopter; MOA ¼ more outdoor activities (14e15 hrs/wk); NA ¼ not available; OK ¼ orthokeratology; PASLs ¼ progressive addition spectacle lenses; PBSLs ¼ prismatic bifocal
spectacle lenses; PDMCLs ¼ peripheral defocus modifying contact lenses; PDMSLs ¼ peripheral defocus modifying spectacle lenses; Pir ¼ pirenzepine; RGPCLs ¼ rigid gas-permeable contact lenses; SCLs ¼
soft contact lenses; Tim ¼ timolol; USVSLs ¼ undercorrected single vision spectacle lenses.
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Huang et al  Network Meta-analysis: Interventions for Myopia3. Asian children appeared to beneﬁt more from
treatment than white children, and most in-
terventions lose their early effect in the second year.Certain trials caused high heterogeneity across studies,
but removal of them only introduced less pronounced effects
of most interventions, without a signiﬁcant change in the
results, and we did not ﬁnd any statistically signiﬁcant in-
consistencies in the network. This implies that the results are
relatively reliable.
The major advantage of our current meta-analytic
approach over individual trials is the larger sample size
that results from incorporating both direct and indirect evi-
dence. This approach also differs from traditional meta-
analyses in that traditional meta-analyses are characterized
by a series of smaller meta-analyses of different active
comparisons and thus provides less robust information.
Although comparisons between speciﬁc classes of in-
terventions for myopia control have been investigated in
multiple studies, others have been performed only in a
single trial or have never been performed. Thus, a network
meta-analysis makes it possible to both validate previous
empirical evidence of direct comparisons and provide evi-
dence regarding comparisons for which no direct empirical
evidence exists.40
Previous trials suggested that, with the exception of
timolol, drug treatments (especially atropine) showed the
highest efﬁcacy, which is consistent with our results.41 It
remains unclear how atropine slows down myopia
progression. Earlier studies have suggested that this may
be due to the effects of atropine on lens accommodation,
whereas subsequent studies have shown that atropine’s
effects on myopia is via a nonaccommodative pathway in
the retina or sclera.18,19 However, the inevitable side ef-
fects of higher doses of atropine (i.e., glare, photophobia,
and near vision blur) and the rebound phenomenon after
stopping treatment have restricted its widespread clinical
use.42,43 There appears to be a differential dose-dependent
sensitivity to atropine’s impact on myopia progression, pu-
pil size, and accommodation. Low-dose atropine (0.01%) is
still one of the most effective interventions identiﬁed in this
analysis and has been found to induce minimal clinical
symptoms.44 Furthermore, this lower dose does not display
the same rebound effect that has been seen in higher doses.
This makes low-dose atropine a deﬁnite candidate treatment
for myopia progression, although this result needs to be
replicated in other populations.
Alternatively, pirenzepine, a selective antimuscarinic
agent, represents a viable alternative to atropine for the
control of myopia progression. Pirenzepine is less likely to
produce pupillary dilatation and cycloplegia with moderate
effects in myopia control.45,46 Of note, the analysis of pir-
enzepine was limited by involvement of only 2 articles;
thus, further trials with larger sample sizes are required to
conﬁrm its effect.
Multifocal spectacle lenses have been tested in control-
ling the progression of myopia for several years, but their
efﬁcacy is controversial.47,48 A previous meta-analysis21
indicated that multifocal spectacle lenses slowed myopia
progression by a mean of 0.25 D in school-aged childrencompared with single vision spectacle lenses. In the current
study, our results suggest only modest effects of bifocal
spectacle lenses and progressive addition spectacle lenses.
Furthermore, there was no signiﬁcant difference between
bifocal spectacle lenses and progressive addition spectacle
lenses in pairwise comparison. As for speciﬁcally designed
multifocal spectacle lenses (prismatic bifocal spectacle len-
ses), our meta-analysis showed that they have a moderate
effect in myopia control, but this was not statistically sig-
niﬁcant with wide CrIs. This is partly because only 1 rele-
vant RCT was included, so further trials are warranted.
Overall, multifocal spectacle lenses do not seem to be a
viable option for controlling progression of myopia.
In terms of contact lenses, orthokeratology has been
shown to be an effective treatment in controlling progres-
sion of myopia.49,50 Orthokeratology ﬂattens the central
cornea while steeping the midperipheral cornea to reduce
relative peripheral hyperopia, which may slow the elonga-
tion of the axial length.51,52 However, orthokeratology is not
in widespread use because of a variety of possible issues,
such as the additional skills required by practitioners for
ﬁtting these lenses, the discomfort during overnight wear,
the cost, and the risks of infective keratitis.53e55 In recent
years, soft contact lenses with myopia control features that
create additional myopic defocus on the retina have gener-
ated great interest in myopia control.33 Our results showed
that peripheral defocus modifying contact lenses were
superior to peripheral defocus modifying spectacle lenses.
Similar to other interventions, the limited relevant RCTs
included in this meta-analysis showed wide CrIs thus,
more RCTs are required to demonstrate its efﬁcacy. In
comparison, other contact lenses such as standard rigid gas-
permeable contact lenses and conventional soft contact
lenses showed no effect on myopia control in our study.
A previous review has indicated that increasing outdoor
activities may be a simple strategy to reduce the risk of
myopia progression.23 However, in the current study, only 1
RCT of outdoor activities contributed to the analysis, and
the effect was modest. Further trials are required to
elucidate the value of this intervention.
Some epidemiologic studies have reported racial differ-
ences between childhood myopia prevalence in Asians and
white subjects within the same country, highlighting the po-
tential role of ethnicity.56,57 In accordance with previous
studies,21 we found that Asians appeared to beneﬁt more
from treatment than white patients. This ﬁnding may be
explicable on the basis of an increased genetic
susceptibility of Asians to myopia or a faster rate of
progression in Asians. Also similar to previous studies,58,59
our study found that most interventions lose their early ef-
fect in the second year, which may be due to increased age.
Study Limitations
There are some inherent limitations in this analysis that
should be highlighted. Optical interventions vary for each
individual patient. For example, multifocal spectacle lenses
have different refractive powers for each patient, and the off-
axis effects of orthokeratology vary with refractive correction.
Both placebo and single vision spectacle lenses are used as705
Ophthalmology Volume 123, Number 4, April 2016controls. The quality of trials conducted and reporting varied
(some studies were not double-blind). There was a wide
variation in subject age (mean age range, 8.3e14.0 years),
but because studies reported only the age range or mean, data
were insufﬁcient to determine how treatment varies with age.
Our study provides information on the efﬁcacy but not the
safety of different treatment options because of lack of data
within the included articles. Clinical decisions on any inter-
vention require information on efﬁcacy, short-term/long-term
beneﬁts, and the risks of side effects, so additional exami-
nation of the safety of these interventions is important. In
addition, high heterogeneity was found in some combina-
tions, and most interventions are based on indirect compari-
sons (113 pairs). More trials are required to conﬁrm the
results from these indirect comparisons.
The fundamental challenge in this analysis is the lack of
sufﬁcient data on some treatments, which results in wide
CrIs. Future trials with larger sample sizes are required to
provide better-quality data to help establish the effect of
various interventions in controlling myopia. In addition, the
possible additive or even synergistic effects of different
combinations (e.g., combined atropine and contact lens
treatments) have not, to date, been adequately addressed.
This is certainly a worthy question for future studies and
may help to provide treatments for myopic progression that
are both effective and easily tolerated by the patient.
Notwithstanding these limitations, it is unlikely that the
number of head-to-head trials necessary to address all these
clinical questions will be conducted. At least 136 trials are
needed to compare all interventions of myopia control, and
in their absence, our network meta-analysis provides a
valuable approach to the issue.
In conclusion, on the basis of evidence from the available
RCTs used in this analysis, the following evidence-based
guidelines might be proposed. (1) Rigid gas-permeable
contact lenses, conventional soft contact lenses, timolol,
and undercorrected single vision spectacle lenses are inef-
fective in slowing the progression of myopia in children. (2)
Atropine, pirenzepine, orthokeratology, soft contact lenses
with myopia control features (peripheral defocus modifying
designs), and progressive addition spectacle lenses are
effective and produce a statistically signiﬁcant reduction of
myopia progression in terms of refraction or axial length. (3)
The introduction of myopia treatments into clinical practice
may be limited by side effects (e.g., atropine 1%), cost and
complexity (e.g., orthokeratology), and limited effectiveness
(e.g., progressive add spectacle lenses). This leaves low-
dose atropine (0.01%), pirenzepine, and soft contact lenses
with myopia control features (e.g., peripheral defocus
modifying designs) as viable options for the active man-
agement of myopia progression.References
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